Xing Liu, Xinjian Li, Shenglin Xiong, Haipeng Zhang, Rong Suo, Xu Zhang, Daiqi Liu, Huaying Fu, Tong Liu, Guangping Li
BACKGROUND:  Recently, the mechanism of thrombogenesis has taken a new direction with the involvement of neutrophil extracellular traps (NETs). However, little is known about the relationship between NETs and thrombogenesis in atrial fibrillation (AF). OBJECTIVE:  Our study aimed to evaluate NETs in AF patients and their potential association with thrombogenesis. In addition, we studied the effect of NETs on thrombogenesis in rat models. METHODS:  A total of 125 AF patients and 172 controls were studied...
September 21, 2023: Thrombosis and Haemostasis
Davide Landolina, Nicola Ammirabile, Davide Capodanno
Not applicable.
September 18, 2023: Thrombosis and Haemostasis
Stavros V Konstantinides
No abstract text is available yet for this article.
September 18, 2023: Thrombosis and Haemostasis
Lasse M Obel, Jes Sanddal Lindholt, Axel Cosmus Pyndt Diederichsen, Christian Kring, Lars Melholt Rasmussen, Anne Alnor, Pernille Just Vinholt
• What is the clinical question being addressed? Ascending and abdominal aortic dilations have been associated with increased platelet activation response suggesting platelets as a potential medical target. • What is the main finding? This study found no higher platelet aggregation or increased frequencies of hyperresponsiveness of platelets in patients with ascending and abdominal aortic dilations.
September 12, 2023: Thrombosis and Haemostasis
Joseph Caprini, MaryAnne Cronin, Nancy Dengler, Eugene Krauss
no abstraact.
September 12, 2023: Thrombosis and Haemostasis
Vanessa Roldán, Eva Soler-Espejo, Francisco Marin
No abstract text is available yet for this article.
September 11, 2023: Thrombosis and Haemostasis
Dario Bongiovanni, Laura Novelli, Francesco Condello, Kilian Kirmes, Jiaying Han, Bastian Wein, Sébastien Elvinger, Giacomo Viggiani, Moritz von Scheidt, Karl-Ludwig Laugwitz, Philip W J Raake, Adnan Kastrati, Mauro Chiarito, Isabell Bernlochner
BACKGROUND:  The pro-thrombotic immature or reticulated platelets (RPs) are known to be elevated in high-risk patients and in different pathological settings. It has been shown that RPs correlate with an insufficient antiplatelet response to antiplatelet agents. RPs are emerging novel predictors of adverse cardiovascular events in cardiovascular disease. This study, using the totality of existing evidence, evaluated the prognostic role of RPs in patients with coronary artery disease...
September 11, 2023: Thrombosis and Haemostasis
Bicheng Li, Minqiao Lu, Hui Wang, Siqi Sheng, Shuyuan Guo, Jia Li, Ye Tian
Background and aims Intra-plaque hemorrhage (IPH) leads to rapid plaque progression and instability through upregulation of matrix metalloproteinases (MMPs) and collagen degradation. Hemoglobin-derived hemin during IPH promotes plaque instability. We investigated whether hemin affect MMPs overexpression in macrophages and explored the underlying mechanisms. Methods In vivo, hemorrhagic plaque models were established in rabbits and ApoE-/- mice. Ferrostatin-1 was used to inhibit ferroptosis. Plaque size, collagen, and MMP2/9 levels were evaluated using immunohistochemistry, H&E, Sirius Red, and Masson staining...
September 11, 2023: Thrombosis and Haemostasis
María Asunción Esteve-Pastor, Eva Soler, Francisco Marín
No Abstract.
September 7, 2023: Thrombosis and Haemostasis
Tessa Elling, Eelko Hak, Jens H J Bos, Vladimir Tichelaar, Nic J G M Veeger, Karina Meijer
Introduction Current guideline suggests a switch from vitamin K antagonist (VKA) to direct oral anticoagulant (DOAC) in patients with low time in therapeutic range (TTR<70%). Poor INR control may be the result of poor compliance, and might therefore be associated with subsequent DOAC intake. Therefore, this study evaluates the effect of previous TTR and other measures of INR control on DOAC non-adherence and non-persistence, in patients who switched from VKA to DOAC. Methods 437 patients who switched from VKA to DOAC between 2012 and 2019 were included using data from Certe Thrombosis Service, IADB...
September 6, 2023: Thrombosis and Haemostasis
Silvia Maria Grazia Trivigno, Mauro Vismara, Ilaria Canobbio, Serena Rustichelli, Federico Galvagni, Maurizio Orlandini, Mauro Torti, Gianni Francesco Guidetti
The C-type lectin receptor CD93 is a single pass type I transmembrane glycoprotein involved in inflammation, immunity, and angiogenesis. This study investigates the role of CD93 in platelet function. CD93 KO mice and WT controls were compared in this study. Platelet activation and aggregation were investigated by flow cytometry and light transmission aggregometry, respectively. Protein expression and phosphorylation were analyzed by immunoblotting. Subcellular localization of membrane receptors was investigated by wide-field and confocal microscopy...
September 5, 2023: Thrombosis and Haemostasis
Takeshi Wada, Satoshi Gando
Two phenotypes of disseminated intravascular coagulation (DIC) are systematically reviewed. DIC is classified into thrombotic and fibrinolytic phenotypes characterized by thrombosis and hemorrhage, respectively. Major pathology of DIC with thrombotic phenotype is the activation of coagulation, insufficient anticoagulation with endothelial injury, and plasminogen activator inhibitor-1 (PAI-1)-mediated inhibition of fibrinolysis, leading to microvascular fibrin thrombosis and organ dysfunction. DIC with fibrinolytic phenotype is defined as massive thrombin generation commonly observed in any type of DIC, combined with systemic pathologic hyperfibrinogenolysis caused by underlying disorder that results in severe bleeding due to excessive plasmin formation...
September 1, 2023: Thrombosis and Haemostasis
Jinchao Yu, Tianfa Wang, XiaoHan Zhang, Qing Chen, Yajun Hu, Qiaoyan Liang, Yun Shi, Yuxiong Wang, Yanling Zhang, Min Yu, Bing Zhao
Classical anticoagulants and antiplatelets are associated with high frequencies of bleeding complications or treatment failure when used as single agents. Thrombin plays an important role in the blood coagulation system. GP IIb/IIIa is the central receptor of platelets, which can recognize the Arg-Gly-Asp (RGD) sequence and activate platelets. We have constructed a novel dual-target peptide (PTIP) based on the direct thrombin inhibitor peptide (DTIP) via molecular simulation and homology modeling. PTIP was expressed at high levels in Pichia pastoris...
September 1, 2023: Thrombosis and Haemostasis
Hao-Ming He, Yi-Nong Chen, Ji-Lang Zeng, Shu-Wen Zheng, Long-Yang Zhu, Zhe Wang, Si-Qi Jiao, Fu-Rong Yang, Yi-Hong Sun
BACKGROUND:  The Age-D-dimer-Albumin (ADA), the CREDO-Kyoto, and the PARIS scores have been established to predict thrombotic events. However, the prognostic performance of these scores compared to the GRACE score in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) has not been reported. METHODS:  Consecutive AMI patients treated with PCI were retrospectively enrolled at a teaching hospital in China from January 2016 to December 2019...
August 29, 2023: Thrombosis and Haemostasis
Sukrit Treewaree, Gregory Y H Lip, Rungroj Krittayaphong
BACKGROUND:  Atrial fibrillation (AF) Better Care (ABC) pathway adherence is associated with improved outcomes. Clinical trials have shown that non-vitamin K antagonist oral anticoagulants (NOACs) are as least as effective as warfarin for stroke prevention in AF patients. The Win Ratio method, analyzing hierarchical composite outcomes considering event timing and severity, has limited data on its use in Asians. OBJECTIVES:  We aim to apply Win Ratio in a registry to access the comparative effectiveness of NOACs versus warfarin and ABC adherence versus nonadherence in Asian patients with AF...
August 25, 2023: Thrombosis and Haemostasis
David J Schneider
August 24, 2023: Thrombosis and Haemostasis
Farahnaz Rayatdoost, Till Braunschweig, Herbert Schöchl, Rolf Rossaint, Oliver Grottke
BACKGROUND:  Andexanet alfa (andexanet) is a reversal agent for use in patients with life-threatening or uncontrolled bleeding treated with oral factor Xa (FXa) inhibitors. There are limited data on the dose-response relationship of andexanet and FXa inhibitor-related bleeding. OBJECTIVE:  The aim of this study was to assess the dose-related effectiveness of andexanet in reducing blood loss, improving survival, and reversing apixaban anticoagulation in a porcine polytrauma model...
August 21, 2023: Thrombosis and Haemostasis
Rasa H Medovic, Ivan M Srejovic, Marija V Medovic, Isidora M Milosavljevic, Marina R Nikolic, Aleksandra Z Stojanovic, Milos B Kuzmanovic, Predrag M Djurdjevic, Sergey B Bolevich, Vladimir P Fisenko, Vladimir Lj Jakovljevic, Zoran R Igrutinovic
BACKGROUND:  Few previous studies indicated the role of oxidative stress in the pathogenesis of childhood idiopathic thrombocytopenic purpura (ITP), but there are little data regarding changes in redox balance in different forms of the disease, and changes after therapeutic procedures. We aimed to investigate the values of pro-oxidants and antioxidative capacity in various forms of ITP before and after the applying therapy. MATERIALS AND METHODS:  The research included 102 children, classified into the following groups: (1) newly diagnosed ITP (ndITP), (2) persistent ITP, (3) chronic ITP (chITP), and (4) control groups: (A) healthy control and (B) previously experienced ITP-healthy children who had been suffering from ITP earlier...
August 21, 2023: Thrombosis and Haemostasis
Yasushi Ueki, Jonas Häner, Sylvain Losdat, Giuseppe Gargiulo, Hiroki Shibutani, Sarah Bär, Tatsuhiko Otsuka, Raminta Kavaliauskaite, Vera Mitter, Fabrice Temperli, David Spirk, Stefan Stortecky, George Siontis, Marco Valgimigli, Stephan Windecker, Clemens Gutmann, Konstantinos C Koskinas, Manuel Mayr, Lorenz Raber
OBJECTIVE: The effect of the PCSK9 inhibitor alirocumab on platelet aggregation among patients with acute myocardial infarction (AMI) remains unknown. We aimed to explore the effect of alirocumab added to high-intensity statin therapy on P2Y12 reaction unit (PRU) among AMI patients receiving dual antiplatelet therapy (DAPT) with a potent P2Y12 inhibitor (ticagrelor or prasugrel). In addition, we assessed circulating platelet-derived non-coding RNAs (microRNAs and YRNAs). METHODS: This was a pre-specified, powered, pharmacodynamic substudy of the PACMAN trial, a randomized, double-blind trial comparing biweekly alirocumab (150mg) versus placebo in AMI patients undergoing percutaneous coronary intervention...
August 18, 2023: Thrombosis and Haemostasis
Shqipdona Lahu, Kristin Adler, Katharina Mayer, Ralph Hein-Rothweiler, Isabell Bernlochner, Gjin Ndrepepa, Stefanie Schüpke, Stefan Holdenrieder, Dario Bongiovanni, Karl-Ludwig Laugwitz, Heribert Schunkert, Meinrad Gawaz, Steffen Massberg, Adnan Kastrati, Götz Münch
BACKGROUND AND AIMS:  Glycoprotein VI (GPVI) is the major platelet-specific collagen receptor. GPVI shedding with generation of soluble GPVI (sGPVI) is an endogenous feedback mechanism preventing platelet overstimulation. sGPVI has not been investigated in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI), especially regarding its potential value as a predictor of ischemic and bleeding risk. METHODS:  Baseline plasma sGPVI levels were available in 318 patients with CCS undergoing PCI...
August 17, 2023: Thrombosis and Haemostasis
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.